ClinicaliQ Trial Snapshot
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Active Not Recruiting • Phase III • Oncology • NCT04487080.
- Two drug combination therapy compared with single drug treatment for advanced lung cancer with specific genetic mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Amivantamab, Osimertinib, Lazertinib, Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 1074 participants